https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiscovery_and_development_of_angiotensin_receptor_blockers%2F40%2FenTranslations:Discovery and development of angiotensin receptor blockers/40/en - Revision history2026-05-04T21:44:40ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/40/en&diff=131497&oldid=prevFuzzyBot: Importing a new version from external source2024-03-28T01:25:31Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>ARBs have a large [[therapeutic index]] and therefore their (mostly low) oral bioavailability does not appear to be of clinical significance.<br />
As can be seen in table 1, these drugs are highly plasma protein-bound and therefore oral administration once a day should provide sufficient [[antihypertensive]] effects.<br />
Around 14% of orally ingested losartan is metabolized to its 5-carboxylic acid [[metabolite]] EXP 3174. As mentioned before, candesartan cilexetil and olmesartan medoxomil are inactive ester prodrugs that are completely hydrolyzed to their active forms by [[esterases]] during [[Absorption (pharmacokinetics)|absorption]] from the [[gastrointestinal tract]]. These three metabolites are more potent AT<sub>1</sub> receptor antagonists than their [[prodrugs]]. The other ARBs do not have active metabolites.</div>FuzzyBot